Business Context and Reporting Period
This Form 8-K filing by Syndax Pharmaceuticals Inc. covers events occurring on March 29, 2017, and March 31, 2017. The report details changes to the composition of the Board of Directors, including the election of a new director and the resignation of an existing director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and compensation arrangements.
Material Changes
- Board Election: Keith A. Katkin was elected to the Board of Directors to fill the vacancy left by Richard P. Shea, who resigned in February 2017 to become the Company's Chief Financial Officer.
- Committee Appointments: Mr. Katkin was appointed to the Audit Committee and the Nominating and Corporate Governance Committee.
- Board Resignation: George W. Sledge, Jr., M.D., notified the Board of his resignation as a Class II director, effective after the annual meeting of stockholders on May 17, 2017. He will continue serving on the Scientific Advisory Board.
Guidance, Outlook, and Compensation
The filing outlines the compensation package for the newly elected director, Keith A. Katkin:
- Cash Compensation: $35,000 annual retainer for Board service, $8,500 for Audit Committee service, and $4,000 for Nominating and Corporate Governance Committee service, paid in quarterly installments.
- Equity Award: A one-time option to purchase 25,000 shares of common stock, vesting monthly over a three-year period (1/36 per month).
- Future Awards: Eligibility for annual option awards subject to continued service.
- Other: Reimbursement for travel expenses and execution of a standard Indemnification Agreement.
There is no forward-looking guidance, risk disclosure, or discussion of unusual items in this specific filing.
Investor Verification Checklist
- Verify the effective date of George W. Sledge, Jr.'s resignation relative to the May 17, 2017 annual meeting.
- Confirm the vesting schedule details for the 25,000 share option granted to Keith A. Katkin.
- Review the Company's Non-Employee Director Compensation Policy for potential future annual option awards.
- Check for any related person transactions involving the new director, though none were disclosed in this filing.